Durvalumab as Consolidation for Patients LS-SCLC

Small-Cell Lung Cancer (SCLC) accounts for 10% to 15% of new lung cancers and is a highly aggressive neuroendocrine tumor. In the past 30 years, the treatment of SCLC has made very limited progress, and basically made breakthroughs in radiotherapy and chemotherapy. With the advent of the immune era, immunotherapy has achieved initial results in the treatment of SCLC. Approximately one-third of patients with small cell lung cancer are in limited-stage (LS-SCLC) disease at first diagnosis. Except for a very small number of patients with T1-2N0 who can be treated with surgery or stereotactic radi

Trial Details

NCT ID

NCT07055581

Phase

PHASE2

Sponsor

Qian Chu

Status

RECRUITING

Cancer Type

Lung Cancer

Interventions

Induction Durvalumab +etoposide/platinum +Radiochemotherapy+ durvalumab maintenance

Locations (sample)

Zhengzhou, Henan, China|34.75778,113.64861
Wuhan, Hubei, China|30.58333,114.26667

Key Eligibility Criteria

Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF…
Histologically or cytologically confirmed small cell lung cancer
Limited-stage, defined as stage I-III SCLC (T any, N any, M0). Patients who are Stage I or II must be medically inoperable as determined by investi…
Age \> 18 years.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →